Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
-0.08 (-0.75%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.03 - 10.69
52 week 4.50 - 11.69
Open 10.65
Vol / Avg. 1.68M/1.65M
Mkt cap 769.76M
P/E     -
Div/yield     -
EPS -0.38
Shares 73.10M
Beta 2.69
Inst. own 27%
Aug 8, 2016
Q2 2016 Inovio Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 25, 2016
Inovio Pharmaceuticals Inc at UBS Global Healthcare Conference
May 9, 2016
Q1 2016 Inovio Pharmaceuticals Inc Earnings Release
May 9, 2016
Q1 2016 Inovio Pharmaceuticals Inc Earnings Call - Webcast
Mar 14, 2016
Q4 2015 Inovio Pharmaceuticals Inc Earnings Release
Mar 14, 2016
Q4 2015 Inovio Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -99.17% -71.73%
Operating margin -190.51% -84.50%
EBITD margin - -82.24%
Return on average assets -15.18% -16.84%
Return on average equity -18.61% -20.35%
Employees 157 -
CDP Score - -


10480 Wateridge Cir
SAN DIEGO, CA 92121-5773
United States - Map
+1-858-5976006 (Phone)
+1-858-4041392 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
David B. Weiner Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Nancy J. Wysenski Director
Age: 57
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters